Format

Send to

Choose Destination
Rev Esp Cardiol (Engl Ed). 2019 Apr;72(4):305-316. doi: 10.1016/j.rec.2018.03.009. Epub 2018 Mar 30.

Direct Oral Anticoagulants Versus Vitamin K Antagonists in Real-life Patients With Atrial Fibrillation. A Systematic Review and Meta-analysis.

[Article in English, Spanish]

Author information

1
Departamento de Cardiología, Hospital La Paz, Madrid, Spain. Electronic address: escobar_cervantes_carlos@hotmail.com.
2
Servicio de Cardiología, Hospital del Mar, Barcelona, Spain.
3
Servicio de Cardiología, Hospital Costa del Sol, Marbella, Málaga, Spain.
4
Institut d'Investigació Biomèdica Sant Pau (IIB Sant Pau), CIBER Epidemiología y Salud Pública CIBERESP, Barcelona, Spain.

Abstract

INTRODUCTION AND OBJECTIVES:

To assess the effectiveness of direct oral anticoagulants vs vitamin K antagonists in real-life patients with atrial fibrillation.

METHODS:

A systematic review was performed according to Cochrane methodological standards. The results were reported according to the PRISMA statement. The ROBINS-I tool was used to assess risk of bias.

RESULTS:

A total of 27 different studies publishing data in 30 publications were included. In the studies with a follow-up up to 1 year, apixaban (HR, 0.93; 95%CI, 0.71-1.20) and dabigatran (HR, 0.95; 95%CI, 0.80-1.13) did not significantly reduce the risk of ischemic stroke vs warfarin, whereas rivaroxaban significantly reduced this risk (HR, 0.83; 95%CI, 0.73-0.94). Apixaban (HR, 0.66; 95%CI, 0.55-0.80) and dabigatran (HR, 0.83; 95%CI, 0.70-0.97) significantly reduced the major bleeding risk vs warfarin, but not rivaroxaban (HR, 1.02; 95%CI, 0.95-1.10), although with a high statistical heterogeneity among studies. Apixaban (HR, 0.56; 95%CI, 0.42-0.73), dabigatran (HR, 0.45; 95%CI, 0.39-0.51), and rivaroxaban (HR, 0.66; 95%CI, 0.49-0.88) significantly reduced the risk of intracranial bleeding vs warfarin. Reduced doses of direct oral anticoagulants were associated with a slightly better safety profile, but with a marked reduction in stroke prevention effectiveness.

CONCLUSIONS:

Data from this meta-analysis suggest that, vs warfarin, the stroke prevention effectiveness and bleeding risk of direct oral anticoagulants may differ in real-life patients with atrial fibrillation.

KEYWORDS:

Anticoagulantes orales directos; Apixaban; Apixabán; Atrial fibrillation; Clinical practice; Dabigatran; Dabigatrán; Direct oral anticoagulants; Fibrilación auricular; Meta-analysis; Metanálisis; Práctica clínica; Rivaroxaban; Rivaroxabán; Warfarin; Warfarina

PMID:
29606361
DOI:
10.1016/j.rec.2018.03.009

Supplemental Content

Full text links

Icon for Ediciones Doyma, S.L.
Loading ...
Support Center